Accelr8 Technology Corporation
Diagnostics company reports loss of $0.04 per share
Published in Healthcare Mergers, Acquisitions and Ventures Week, April 17th, 2004
In the comparable quarter of fiscal 2003, Accelr8, whose fiscal year ends July 31, reported a net loss of $281,000, or $0.03 per share, on net revenues of $202,000.
"During the quarter," said Thomas Geimer, Accelr8's chairman and chief executive officer, "we advanced our development of BACcelr8r, an analytical system that will integrate our three existing technologies - OptiChem, QuanDx, and YoDx - into a platform of measurement instruments and disposable analytical test chips for use in medical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Advanced Cell Technology Corp.
Geron receives favorable ruling in nuclear-transfer patent interference - Altana AG
Pharmaceutical company's sales increased 5% in 2003 - Antares Pharma, Inc.
U.S. patent issued on Valeo, a needle-free injector device - AxioMed Spine Corp.
Spinal implant device firm names David K. Floyd president, CEO - Barr Pharmaceuticals, Inc.
Pharmaceutical company announces stock split distribution - Bayer Group
Pharmaceutical firm aims to increase EBITDA margin - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
